[go: up one dir, main page]
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates

Cellular & Molecular Immunology volume 17, pages 776–778 (2020)Cite this article

Subjects

Breast cancer has long been characterized as a B-cell-related disease with regard to the immune response. For example, data have indicated that B-cell receptor (BCR) recombination read recoveries from breast cancer exome (WXS) files revealed an increased disease-free survival (DFS) rate.1 However, the antigens stimulating the B-cell response have not been well characterized, particularly via immunogenomics analyses. Thus, we evaluated the net charge per residue (NCPR) for CDR3s, for BCRs expressed on tumor-infiltrating lymphocytes (TILs), to assess its electrostatic complementarity with TP53-mutant amino acids (AAs), because the CDR3 loop domain is the most important part of the BCR polypeptide for antigen-binding specificity.2

Two algorithms, termed the extended and abbreviated approaches (Supporting Online Material (SOM), Methods), were used to determine complementarity scores (CSs) based on the CDR3-mutant TP53 AA electrostatic complementarities. Both algorithms assessed complementarity using the NCPR for the BCR CDR3s and the values for the TP53 mutants based on the difference between the amino acid charges of mutant and wild-type TP53 (SOM, Methods; Tables S1-S5).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Tong, W. L. et al. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Res. Treat. 173, 167–177 (2019).

    Article  CAS  Google Scholar 

  2. Davis, M. M. The evolutionary and structural ‘logic’ of antigen receptor diversity. Semin. Immunol. 16, 239–243 (2004).

    Article  CAS  Google Scholar 

  3. Mauro, J. A. & Blanck, G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene 536, 398–406 (2014).

    Article  CAS  Google Scholar 

  4. Clark, K. R. et al. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. Int. J. Immunogenet. 46, 31–37 (2019).

    Article  CAS  Google Scholar 

  5. Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–30. (2018).

    Article  CAS  Google Scholar 

  6. Chobrutskiy, B. I., Zaman, S., Diviney, A., Mihyu, M. M. & Blanck, G. T-cell receptor-alpha CDR3 domain chemical features correlate with survival rates in bladder cancer. J. Cancer Res. Clin. Oncol. 145, 615–23. (2019).

    Article  CAS  Google Scholar 

  7. Bedke, J. & Stenzl, A. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? Expert Rev. anticancer Ther. 13, 1399–1408 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the contributions of USF research computing and the taxpayers of the State of Florida. J.F.A., B.I.C., M.Y., S.F., and J.S.P. are recipients of RISE fellowships from the USF Morsani College of Medicine.

Author information

Authors and Affiliations

  1. Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, United States

    Juan F. Arturo, Boris I. Chobrutskiy, Michelle Yeagley, Dhruv N. Patel, Shayan Falasiri, Jay S. Patel & George Blanck

  2. Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, United States

    George Blanck

Authors
  1. Juan F. Arturo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boris I. Chobrutskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelle Yeagley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dhruv N. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shayan Falasiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jay S. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. George Blanck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Blanck.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arturo, J.F., Chobrutskiy, B.I., Yeagley, M. et al. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. Cell Mol Immunol 17, 776–778 (2020). https://doi.org/10.1038/s41423-019-0328-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-019-0328-8

Search

Advanced search

Quick links